The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Subjects, 18 to 60 years of age, inclusive for Parts 1 and 2
Subjects, 12 to 60 years of age, inclusive for Parts 3 and 5
No clinically significant laboratory, ECG, or vital signs results.
Subjects with VWD who are symptomatic, defined as having a history of bleeding or bruising.
Baseline FVIII activity > 50 IU/dL.
Any acute, clinically significant bleeding event requiring surgical or procedural intervention within 7 days prior to receiving study drug.